9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionano.com
Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 344
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, CEO, Secretary & Director | 834,57k | N/D | 1968 |
Mr. Mark Oldakowski | Chief Operating Officer | 603,82k | N/D | 1974 |
Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer | 558,83k | N/D | 1973 |
Ms. Gulsen Kama M.B.A. | Chief Financial Officer | N/D | N/D | N/D |
Mr. Mark Adamchak CPA | VP of Accounting & Controller | N/D | N/D | N/D |
Mr. Jonathan Dixon J.D. | General Counsel | N/D | N/D | 1975 |
Mr. Stanislas Marin M.B.A., M.S. | Vice President of Global Sales | N/D | N/D | N/D |
Ms. Donna Polizio | Global Head of Market Access | N/D | N/D | N/D |
Mr. Cory Kreeck | Global Head of People Operations | N/D | N/D | N/D |
Dr. Klint Rose Ph.D. | Head of Research & Development | N/D | N/D | N/D |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Bionano Genomics, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 10.